Increased Sales and EBITDA
Sales increased approximately 5%, with EBITDA rising by 22% to SEK 235 million, resulting in a margin of 9.8%.
Strong Financial Position
The company's financial position is robust, with a relation of EBITDA to financial liabilities at 0.6x, enabling continued global market offerings.
Growth in Medical Solutions
Notable growth in the In Vitro Diagnostics and Drug Delivery segments, with total sales of SEK 1,355 million and a margin of 10.7%.
Engineered Solutions Performance
Currency-adjusted growth of 4% in Engineered Solutions, with significant 17% growth in Materials due to increased volumes.
Improved Group Financial Metrics
Operating profit rose 22% to SEK 235 million, and cash flow from operating activities increased to SEK 327 million.
Positive Customer Contracts in Drug Delivery
The acquisition of a significant customer contract within Drug Delivery validates the company's strategic direction.